曲美他嗪治疗扩张型心肌病心力衰竭的疗效观察

目的探讨曲美他嗪在扩张型心肌病心力衰竭中的治疗效果。方法将80例扩张型心肌病心力衰竭患者随机分为对照组与观察组各40例,对照组予常规治疗,观察组在常规治疗基础上加用曲美他嗪,对比两组治疗前后心功能指标变化。结果观察组总有效率为82.5%,显著高于对照组的60.0%(P<0.05),观察组治疗后LVEF值显著高于对照组(P<0.01),LVEDD显著低于对照组(P<0.05),CO显著高于对照组(P<0.01),两组均无一例发现药物相关不良反应。结论常规治疗基础上联合曲美他嗪治疗扩张型心肌病心力衰竭,不良反应少,可显著提高治疗效果及患者生活质量,改善患者预后。

Efficacy of Trimetazidine in patients with Heart Failure of Dilated Cardiomyopathy

Objective To study the efficacy of trimetazidine in patients with heart failure of dilated cardiomyopa- thy. Methods 80 patients diagnosed as dilated cardiomyopathy heart failure in our hospital（AVIC 363 hospital） were di- vided into observation group and control group, 40 in each. Patients in control group were given conventional treatment, and trimetazidine was added on top of conventional treatment in observation group. Cardiac function indexes in two groups were compared before and after treatment. Results The total effective rate in observation group was 82.5%, sig- nificantly higher than that of 60% in control group （P〈0. 05）. After treatment, patients in observation group had signifi- cantly higher left ventricle ejection fraction （LVEF） than those in control group （P〈0. 01）, with obviously lower left ventricle end diastolic dimension （LVEDD） （P〈0.01） and higher cardiac output （CO） （P〈0.01）. No adverse drug re- action was found in each group. Conclusion On the basis of conventional treatment, trimetazidine could improve thera- peutic outcomes, quality of life and prognosis of patients with dilated cardiomyopathy heart failure, with rare adverse re- action.